Amgen offers assistance to patients through Amgen Assist 360, Amgen SupportPlus Co-Pay Program, and the Amgen Safety Net Foundation. A complete list of Amgen oncology products and their related assistance programs is provided in the Table.
Amgen Assist 360
Amgen Assist 360 provides resources such as Amgen Reimbursement Counselors to conduct benefit verifications and Amgen Nurse Navigators who can help find resources that are most important to your patients. Please visit Amgen's website for more information. To enroll your patient in the Amgen Nurse Navigator program, download the enrollment form.
Amgen SupportPlus Co-Pay Program
The Amgen SupportPlus Co-Pay Program is here to help eligible commercially insured patients pay for their out-of-pocket prescription costs.
Pay as little as $0 out-of-pocket for each dose or cycle (excluding Prolia and EVENITY)*
For Prolia and EVENITY, pay as little as $25 out-of-pocket for each dose
Can be applied to deductible, co-insurance, and co-payment†
No income eligibility requirement.
* $25 out-of-pocket cost for each dose of Prolia (denosumab) and EVENITY (romosozumab-aqqg) through Amgen SupportPlus.
† Terms, conditions, and program maximums apply. Other restrictions may apply. See the Amgen SupportPlus Co-Pay Program Terms and Conditions for details. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.
Patients can register for this program by visiting AmgenSupportPlus.com. For more information, call (866) AMG-ASST (1-866-264-2778).
Amgen Safety Net Foundation
This foundation assists patients who are uninsured or their insurance plan excludes the prescribed Amgen medicine or its generic/biosimilar. Patients may be eligible if they:
Have lived in the U.S. or its territories for six months or longer
Satisfy income eligibility requirements
Are uninsured or their insurance plan excludes the Amgen medicine or its generic/biosimilar
Certain Medicare Part D patients with product coverage who cannot afford their out of pocket costs may be eligible. It is required that they are able to demonstrate:
Their inability to afford the medicine
Their ineligibility for Medicaid or Medicare’s low-income subsidy (Extra Help)
They have satisfied all payer guidelines and Prior Authorization (PA) requirements prior to applying for assistance
They do not have any other financial support options
To apply to the Amgen Safety Net Foundation, please visit our website, and select the prescribed medicine.
Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia; CD19-positive B-cell precursor acute lymphoblastic leukemia in first or second complete remission, with minimal residual disease
Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastasis from solid tumors; unresectable giant-cell tumor of the bone; hypercalcemia of malignancy refractory to bisphosphonate therapy
Relapsed or refractory multiple myeloma after 1 to 3 lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone; monotherapy for relapsed or refractory multiple myeloma who have received 1 or more lines of therapy
Mvasi (bevacizumab-awwb) Indications
Treatment of recurrent glioblastoma; treatment of persistent, recurrent, or metastatic cervical cancer, in combination with chemotherapy; treatment of metastatic colorectal cancer, in combination with chemotherapy or after disease progression with a bevacizumab-containing regimen; treatment of unresectable, locally advanced, recurrent, or metastatic nonsquamous NSCLC, in combination with carboplatin and paclitaxel; treatment of metastatic renal-cell carcinoma, in combination with interferon-alfa; treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer
Nplate (romiplostim) Indications
Treatment of patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy; treatment of pediatric patients ≥1 year of age with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy
Riabni (rituximab-arrx) Indications
Treatment of adult patients with non-Hodgkin’s Lymphoma (NHL), including relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent; previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy; in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; non-progressing, low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy; previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens; treatment of adult patients with chronic lymphocytic leukemia (CLL), including previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide
Report Broken Links
Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?